Search Results
subscales. The MEQ-30 has demonstrated sensitivity in assessing the effects of a range of psychedelic compounds, including LSD ( Schmid & Liechti, 2018 ), MDMA ( Lyvers & Meester, 2012 ), psilocybin ( Barrett et al., 2015 ), ayahuasca ( Schenberg, Tofoli
, DMT, and other substances, as seen in Table 1 . Table 1. Lifetime use of hallucinogens Hallucinogen Mean (SD) Median Range LSD 27.51 (104.99) 1.00 0–1,000 Mushrooms 25.64 (94.08) 5.00 0–1,000 MDMA 19.55 (82.7) 0.00 0–5 DMT 3.66 (11.21) 0.00 0
, M. T. , Reed , S. , & Aggarwal , R. ( 2020 ). Culturally-informed research design issues in a study for MDMA-assisted psychotherapy for posttraumatic stress disorder . Journal of Psychedelic Studies , 4 ( 1 ), 40 – 50 . https://doi.org/10
general public [Bachelor's thesis, University of Twente] . http://purl.utwente.nl/essays/82465 . Therapeutic Goods Administration ( 2023 , Feb 3). Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists
, K. H. , Heifets , B. D. , Hibicke , M. , Mitchell , J. , et al. ( 2021 ). Hallucinogens in mental health: Preclinical and clinical studies on LSD, psilocybin, MDMA, and ketamine . The Journal of Neuroscience: The Official Journal of the
Psychedemia: Charting the future of interdisciplinary Psychedelic Studies
Introduction to the Special Issue
of harm in clinical trials of MDMA. The stakes of adequately communicating these risks to patients is high, especially since P-AT is anticipated as a treatment option for PTSD, which disproportionately impacts historically marginalized groups with
-schedule psilocybin and MDMA, allowing prescriptions by “authorised psychiatrists” for specific indications (PTSD and treatment-resistant depression, respectively) as of July 1, after an “aggressive” lobbying campaign led by Mind Medicine Australia (MMA) ( Blau
methylenedioxy methamphetamine (MDMA) ( Dore et al., 2019 ; Kolp et al., 2014 ). Since the ego remains intact, ketamine-induced psycholytic states are useful to relationally process traumas and developmental arrest. A person may enter a state of “new mind” that
studies showing no benefit and greater discontinuation rates (30%) compared to placebo (17%), hypothesized to be secondary to unreported adverse effects ( Friedman et al., 2007 ). Given these limitations, novel therapeutics, such as MDMA
), lifetime phencyclidine (PCP) use (variable PCPFLAG; 0 = never used, 1 = ever used), lifetime 3,4-methylenedioxymethamphetamine (MDMA/ecstasy) use (variable ECSFLAG for 2013–2014 and ECSTMOFLAG for 2015–2019; 0 = never used, 1 = ever used), and lifetime
